Bernard Fox on Significance of Immunoscore Validation Project
Bernard A. Fox, PhD, chief, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute at Providence Portland Medical Center, discusses the significance of the Immunoscore Validation Project.
Bernard A. Fox, PhD, chief, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute at Providence Portland Medical Center, discusses the significance of the Immunoscore Validation Project.
A recent study of the Immunoscore was a Society for Immunotherapy of Cancer-led international consortium aimed at evaluating the standardized assay in routine clinical settings. Specifically, it looked at patients with stage I, II, and III colon cancer who did not receive neoadjuvant treatment. Results showed that the treatment to recurrence was significantly longer in patients with a high Immunoscore, while patients with a low score were identified as those with high-risk stage II colon cancer.
In regards to immunotherapy, more combination regimens are on the horizon in the field of oncology, Fox explains.
<<<
